Giansun Precision Technology Group
001400
Heilongjiang Tianyouwei Electronics
603202
Joy Kie Corporation
300994
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
US Stock MarketDetailed Quotes
ACRS Aclaris Therapeutics
- 1.270
- +0.080+6.72%
Close Apr 24 16:00 ET
- 1.270
- 0.0000.00%
Post 20:01 ET
137.35MMarket Cap-0.74P/E (TTM)
1.330High1.190Low1.01MVolume1.190Open1.190Pre Close1.28MTurnover1.52%Turnover RatioLossP/E (Static)108.15MShares5.17052wk High0.88P/B84.20MFloat Cap0.95252wk Low--Dividend TTM66.30MShs Float33.880Historical High--Div YieldTTM11.77%Amplitude0.590Historical Low1.271Avg Price1Lot Size
Aclaris Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 74.37%-20.08M | -32.20%-8.94M | 189.59%22M | 40.34%-12.32M | 21.01%-20.82M | -15.92%-78.33M | 64.63%-6.76M | -214.15%-24.56M | -5.02%-20.65M | -25.68%-26.35M |
| Net income from continuing operations | -49.26%-132.07M | -6,375.65%-96.55M | 74.07%-7.59M | 62.85%-10.99M | 39.84%-16.94M | -1.81%-88.48M | 94.60%-1.49M | -46.66%-29.26M | -44.01%-29.57M | -49.87%-28.16M |
| Depreciation and amortization | -6.49%807K | -37.28%143K | -18.26%179K | 11.01%242K | 22.73%243K | 8.28%863K | 20.00%228K | 13.47%219K | 5.83%218K | -4.81%198K |
| Deferred tax | --0 | ---- | ---- | ---- | ---- | ---367K | ---- | ---- | ---- | ---- |
| Other non cash items | 541.05%89.41M | 535.18%85.61M | -52.94%800K | 113.33%200K | 450.00%2.8M | -531.30%-20.27M | -377.06%-19.67M | -22.73%1.7M | 55.88%-1.5M | 33.33%-800K |
| Change In working capital | 16.33%10.92M | -107.49%-994K | 909.45%25.6M | -227.37%-4.68M | -104.82%-9.01M | 885.69%9.39M | 470.47%13.27M | -156.95%-3.16M | 898.64%3.68M | -24.42%-4.4M |
| -Change in receivables | -110.75%-20K | -47.92%25K | -121.18%-18K | -81.18%48K | 62.87%-75K | 33.81%186K | -57.52%48K | 112.50%85K | 6,475.00%255K | -1,920.00%-202K |
| -Change in prepaid assets | -269.20%-4.86M | -207.78%-8.6M | 118.56%1.43M | 137.35%273K | 333.87%2.04M | 42.68%-1.32M | 239.92%7.98M | -466.27%-7.69M | -165.21%-731K | -564.89%-874K |
| -Change in payables and accrued expense | -177.30%-8.13M | 63.87%8.6M | -116.96%-753K | -220.50%-5M | -230.47%-10.98M | 995.63%10.52M | 161.62%5.25M | 30.01%4.44M | 654.21%4.15M | 10.53%-3.32M |
| -Change in other working capital | --23.93M | ---1.02M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 74.37%-20.08M | -32.20%-8.94M | 189.59%22M | 40.34%-12.32M | 21.01%-20.82M | -15.92%-78.33M | 64.63%-6.76M | -214.15%-24.56M | -5.02%-20.65M | -25.68%-26.35M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -250.95%-69.77M | -1,275.14%-88.72M | -91.41%2.8M | 96.57%-674K | -34.75%16.83M | 266.01%46.22M | 179.42%7.55M | 2,573.29%32.53M | 7.36%-19.66M | -13.81%25.8M |
| Net PPE purchase and sale | 90.76%-121K | --0 | --0 | 106.06%14K | 75.59%-135K | -116.36%-1.31M | -320.00%-441K | 44.00%-84K | -24.19%-231K | -237.20%-553K |
| Net intangibles purchase and sale | ---35.81M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | -171.19%-33.84M | -762.16%-52.91M | -91.43%2.8M | 96.46%-688K | -35.61%16.97M | 259.17%47.53M | 184.68%7.99M | 2,286.10%32.62M | 7.63%-19.43M | -12.44%26.35M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -250.95%-69.77M | -1,275.14%-88.72M | -91.41%2.8M | 96.57%-674K | -34.75%16.83M | 266.01%46.22M | 179.42%7.55M | 2,573.29%32.53M | 7.36%-19.66M | -13.81%25.8M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 179.10%74.54M | 152,104.08%74.58M | 125.29%22K | -100.04%-11K | -55K | -63.35%26.71M | 32.43%49K | -690.91%-87K | -63.27%26.74M | 0 |
| Net common stock issuance | 180.43%74.91M | --74.91M | --0 | ---- | ---- | -63.28%26.71M | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | -65.96%32K | --0 | 113.33%32K | ---- | ---- | -40.13%94K | 32.43%49K | --15K | ---- | ---- |
| Net other financing activities | -300.98%-409K | ---333K | ---10K | ---11K | ---55K | -200.00%-102K | --0 | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 179.10%74.54M | 152,104.08%74.58M | 125.29%22K | -100.04%-11K | ---55K | -63.35%26.71M | 32.43%49K | -690.91%-87K | -63.27%26.74M | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -11.92%39.88M | 22.06%47.65M | -26.70%22.83M | -19.86%35.84M | -11.92%39.88M | 65.55%45.28M | -36.68%39.04M | -54.37%31.15M | 23.06%44.72M | 65.55%45.28M |
| Current changes in cash | -183.53%-15.31M | -2,854.30%-23.08M | 214.54%24.82M | 4.16%-13.01M | -627.39%-4.04M | -130.11%-5.4M | 105.12%838K | 219.35%7.89M | -142.52%-13.57M | -106.17%-555K |
| End cash Position | -38.39%24.57M | -38.39%24.57M | 22.06%47.65M | -26.70%22.83M | -19.86%35.84M | -11.92%39.88M | -11.92%39.88M | -36.68%39.04M | -54.37%31.15M | 23.06%44.72M |
| Free cash flow | 29.67%-56.01M | -521.33%-44.75M | 189.28%22M | 41.07%-12.31M | 22.14%-20.95M | -16.81%-79.63M | 62.53%-7.2M | -209.29%-24.64M | -5.20%-20.89M | -27.32%-26.91M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025